Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025)

Standard Biotools has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 25633000.0 for Q4 2025.

Quarterly Liabilities from Discontinued Operations rose 23.21% to 25633000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 25633000.0 through Dec 2025, up 23.21% year-over-year, with the annual reading at 25633000.0 for FY2025, 23.21% up from the prior year.
Liabilities from Discontinued Operations was 25633000.0 for Q4 2025 at Standard Biotools, up from 22214000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 25633000.0 in Q4 2025 and troughed at 20804000.0 in Q4 2024.